CD8A and neoplasm: Traditional tumor vaccines mainly focus on improving the cellular activity of CD8 + T cells, while the screening of tumor antigen dominant CTL epitope peptides is helpful to find new immune active targets that synergistically activate CD8 + T cells, NK cells and DC [163].